MedTrace Logo

Multicenter Selective Lymphadenectomy Trial (MSLT)

NCT00275496 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2001

Last updated 2015-09-02

No results posted yet for this study

Summary

Subjects must be diagnosed with melanoma. All subjects receive Wide Excision (WEX) of their melanoma. If the melanoma meets study requirements, the subject is randomized to receive either (1) no further surgical procedures as part of the study or (2) a Selective Lymphadenectomy with the possibility of a Complete Lymphadenectomy. Subjects are then followed for 10 years.

Conditions

Interventions

PROCEDURE

Sentinel Lymph Node Dissection

Subject has wide excision and sentinel lymph node dissection for primary melanoma.

PROCEDURE

Complete Lymph Node Dissection

Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.

PROCEDURE

Wide Excision

Subject has wide excision only for primary melanoma.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Saint John's Cancer Institute

    lead OTHER

Principal Investigators

  • Donald L Morton, MD · Saint John's Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-11-30
Primary Completion
2012-06-30
Completion
2012-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00275496 on ClinicalTrials.gov